Registry of Lobbyists
| Subject matters | Details | Categories |
|---|---|---|
|
Federal-Provincial Relations, Foreign Affairs, Health, Industry, Intellectual Property, International Trade, Research and Development, Science and Technology, Small Business, Taxation and Finance
|
Annual federal Budgets and Budget updates as it relates to the biopharmaceutical industry
|
Legislative Proposal, Bill or Resolution
|
|
Foreign Affairs, Health, Infrastructure, International Trade, Research and Development, Science and Technology, Small Business, Taxation and Finance
|
Biomanufacturing and Life Sciences Strategy (BLSS) as it relates to the biopharmaceutical industry
|
Policies or Program
|
|
Foreign Affairs, Health, Intellectual Property, International Trade, Research and Development, Science and Technology
|
Canada's Access to Medicines Regime with respect to ensuring that the program allows for the delivery of timely access to needed medicines to the developing world supported by a business climate in Canada that continues to encourage research into further treatment and prevention of disease
|
Policies or Program
|
|
Foreign Affairs, Health, Intellectual Property, International Trade, Research and Development, Science and Technology
|
Canada-United States Regulatory Cooperation Council (RCC) initiatives related to the regulation of biopharmaceutical products
|
Policies or Program
|
|
Environment, Health, Intellectual Property, Research and Development, Science and Technology
|
Canadian Environmental Protection Act and Regulations in respect of modern, science-based regulations to reflect rapidly changing new technologies
|
Legislative Proposal, Bill or Resolution, Regulation
|
|
Health, Research and Development, Science and Technology, Taxation and Finance
|
Canadian Institutes of Health Research (CIHR) Clinical Research Initiative as it relates to public/private research and development partnerships
|
Policies or Program
|
|
Health, Intellectual Property, Research and Development, Science and Technology
|
Common Drug Review Policies as it relates to reimbursement recommendation decision-making process and framework
|
Policies or Program
|
|
Consumer Issues, Federal-Provincial Relations, Health, Intellectual Property, Research and Development, Science and Technology, Taxation and Finance
|
Establish accountability with the federally financed Canadian Agency for Drugs and Technologies in Health (CADTH)
|
Policies or Program
|
|
Health, Intellectual Property, International Trade, Research and Development, Science and Technology
|
Food and Drug Regulations as it relates to data protection and the regulation and protection of biopharmaceutical products
|
Regulation
|
|
Agriculture, Consumer Issues, Foreign Affairs, Health, International Relations, International Trade, Taxation and Finance
|
Food and Drugs Act and Regulations and the Import and Export Permits Act with respect to cross-border trade as it relates to the export of Canadian biopharmaceuticals
|
Legislative Proposal, Bill or Resolution, Regulation
|
|
Foreign Affairs, Health, Intellectual Property, International Relations, International Trade, Research and Development, Science and Technology, Taxation and Finance
|
Free trade agreements as they relate to the biopharmaceutical industry
|
Policies or Program
|
|
Agriculture, Consumer Issues, Health, Intellectual Property, Research and Development, Science and Technology, Taxation and Finance
|
Health Canada's Regulatory Roadmap for Health Products and Food as it relates to the biopharmaceutical industry
|
Regulation
|
|
Health, Intellectual Property, International Trade, Research and Development, Science and Technology, Taxation and Finance
|
Income Tax Act as it relates to biopharmaceutical products
|
Legislative Proposal, Bill or Resolution
|
|
Health, Intellectual Property, International Relations, International Trade, Research and Development, Science and Technology, Taxation and Finance
|
Patent Act as it relates to reporting requirements and pricing guidelines, and the protection of intellectual property in biopharmaceutical products
|
Legislative Proposal, Bill or Resolution
|
|
Health, Intellectual Property, International Relations, International Trade, Research and Development, Science and Technology, Taxation and Finance
|
Patented Medicines (Notice of Compliance) Regulations as it relates to the regulation of intellectual property for biopharmaceutical products
|
Regulation
|
|
Health, Intellectual Property, International Relations, International Trade, Research and Development, Science and Technology, Taxation and Finance
|
Patented Medicines (Notice of Compliance) Regulations with respect to ensuring that patent rights are respected and are internationally competitive
|
Regulation
|
|
Health, Intellectual Property, International Relations, International Trade, Research and Development, Science and Technology, Taxation and Finance
|
Patented Medicines Regulations as it relates to the regulation and protection of biopharmaceutical products
|
Regulation
|
|
Constitutional Issues, Consumer Issues, Federal-Provincial Relations, Health, Research and Development, Science and Technology
|
Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB)
|
Policies or Program
|
|
Consumer Issues, Federal-Provincial Relations, Health, Intellectual Property, International Trade, Research and Development, Science and Technology, Taxation and Finance
|
Proposed pharmacare legislation related to any future national pharmacare program
|
Legislative Proposal, Bill or Resolution
|
|
Health, Intellectual Property, Research and Development, Science and Technology, Taxation and Finance
|
Scientific Research and Educational Design (SR&ED) Tax Credit in respect of updating the system and increasing the expenditure limit for refundable credits
|
Policies or Program
|
|
Health, Intellectual Property, International Trade, Research and Development, Science and Technology, Taxation and Finance
|
Subsequent Entry Biologics (SEBs) as it relates to Regulations, Policies, or Guidelines being developed by Health Canada, specifically the Draft Guidance Document on SEBs, the Notices of Changes to Health Canada's Guidance Documents on Data Protection and Patented Medicines Regulations (Notice of Compliance) Regulations
|
Policies or Program
|
|
Agriculture, Government Procurement, Health, Intellectual Property, International Trade, Research and Development, Science and Technology, Taxation and Finance
|
World Health Organization (WHO) issues concerning the biopharmaceutical industry
|
Policies or Program
|
|
Health, Intellectual Property, International Trade, Research and Development, Science and Technology, Taxation and Finance
|
World Intellectual Property Organization (WIPO) issues concerning the biopharmaceutical industry
|
Policies or Program
|
|
Health, Intellectual Property, International Trade, Research and Development, Science and Technology, Taxation and Finance
|
World Trade Organization (WTO) issues concerning the agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs) with respect to the protection of data, Access to Medicines, and TRIPs "flexibility"
|
Policies or Program
|
Innovative Medicines Canada represents Canada’s innovative pharmaceutical industry. We help our members discover, develop, and deliver innovative medicines and vaccines. Our membership consists of more than 50 companies, from established organizations to fledgling startups, all of whom are revolutionizing healthcare through the discovery and development of new medicines and vaccines. Guided by a strict Code of Ethical Practices, we work with governments, insurance companies, healthcare professionals and stakeholders to advance the field and enhance the wellbeing of Canadians. We are committed to being valued partners in Canada’s healthcare system. We aim to achieve these goals by forming effective alliances and supporting policies, improving Canada’s regulatory environment, widen access to innovative medicines and protect intellectual property.
Bettina Hamelin, President
Address:
55 Metcalfe St.
Suite 1220
Ottawa, ON K1P 6L5
Canada
Telephone number:
343-999-2112
This is the responsible officer name as provided in the most recent registration for the corporation or organization.
| Name | From | To |
|---|---|---|
| Innovative Medicines Canada/Médicaments novateurs Canada | 2024-04-08 | current |
| Innovative Medicines Canada/Médicaments novateurs Canada | 2016-01-04 | 2024-04-08 |
| Canada's Research-Based Pharmaceutical Companies | 2008-08-08 | 2016-01-04 |
| Responsible Officer Name | From (YYYY-MM-DD) | To (YYYY-MM-DD) |
|---|---|---|
| Bettina Hamelin | 2024-04-08 | Current |
| David Renwick | 2023-11-17 | 2024-04-08 |
| Pamela Fralick | 2016-12-01 | 2023-11-17 |
| Elaine Campbell | 2016-06-13 | 2016-12-01 |
| RUSSELL WILLIAMS | 2004-08-19 | 2016-06-13 |
Registrants are required to submit a monthly communication report for each oral and arranged communication with a designated public office holder. The name of the most senior paid officer (i.e. the registrant) will appear on all in-house monthly communication reports, whether or not he/she participated in the communication.
Note: Monthly Communication Reports are due on the 15th day of each month for communications that took place in the previous month.
Results below are sorted by posted date, beginning with the most recent.
Registrants are required to submit a monthly communication report for each oral and arranged communication with a designated public office holder. The name of the most senior paid officer (i.e. the registrant) will appear on all in-house monthly communication reports, whether or not he/she participated in the communication.
Note: Monthly Communication Reports are due on the 15th day of each month for communications that took place in the previous month.
Results below are sorted by posted date, beginning with the most recent.
| Position | Period Held | Last Date Designated Public Office Held |
|---|---|---|
|
Vice President, Research Partnerships
Council of Canada, Natural Sciences and Engineering Research Council of Canada |
August 2015 to July 2017 | July 12, 2017 |
| Position | Period Held | Last Date Designated Public Office Held |
|---|---|---|
|
Law Clerk
Federal Court of Canada, No branch or unit |
July 2013 to August 2014 | Not a designated office |
|
Senior Regulatory Officer
Patented Medicine Prices Review Board, Regulatory Affairs and Outreach |
December 2008 to June 2013 | Not a designated office |
| Position | Period Held | Last Date Designated Public Office Held |
|---|---|---|
|
Senior Advisor, Program Delivery
Health Canada, Office of Nutrition Policy and Promotion |
August 2020 to November 2020 | Not a designated office |
| Position | Period Held | Last Date Designated Public Office Held |
|---|---|---|
|
Legislative Assistant to Albina Guarnieri, M.P. - Parliamentary Secretary to the Minister of Canadian Heritage
Canadian Heritage, Parliament Hill Office |
1994 to March 1998 | Not a designated office |
| Position | Period Held | Last Date Designated Public Office Held |
|---|---|---|
|
COSEP Student, Official Languages Commission
Official Language Commission, Language Commission |
1990 to 1991 | Not a designated office |
| Position | Period Held | Last Date Designated Public Office Held |
|---|---|---|
|
Jr. Research Analyst
Industry Canada, Industrial Analysis |
2004 to 2004 | Not a designated office |
| Position | Period Held | Last Date Designated Public Office Held |
|---|---|---|
|
Vice President, Research Partnerships
Council of Canada, Natural Sciences and Engineering Research Council of Canada |
August 2015 to July 2017 | July 12, 2017 |